Full-Time

Senior Scientist

Translational Cardiac Biology

UntilLabs

UntilLabs

51-200 employees

Advances reversible organ cryopreservation technology

Compensation Overview

$120k - $180k/yr

+ Equity

California, USA

In Person

PhD

Category
Biology & Biotech (2)
,

Get referred to UntilLabs

See people who can refer or advise you

Requirements
  • PhD and/or Postdoctoral training in Cardiac Physiology, Bioengineering, Chemical Engineering, Tissue Engineering, Pharmacology, Toxicology, or a related field, or equivalent (4+ years) of industry experience leading research projects end-to-end
  • Hands-on expertise in cell-based assay development, including experience with primary cells, induced pluripotent stem cell-derived cells, or 3D in vitro models
  • Proven ability to design and execute high throughput screening workflows and analyze multiparametric datasets
  • Demonstrated ability to independently develop and carry out complex experiments in cardiac biology or a related therapeutic area
  • Strong collaboration skills and ability to work in cross-functional teams
  • Ability to thrive in fast-paced environments with a high sense of mission and urgency
Responsibilities
  • Develop clinically translatable healthy in vitro models using primary/immortalized cardiac cells, including induced pluripotent stem cell-derived cardiomyocytes
  • Design and implement high throughput screening experiments to characterize the viability and functional performance of cardiac cells using multi-electrode array, calcium imaging, impedance-based readouts
  • Create and validate complex in vitro 3D cardiac models (e.g., organoids, engineered heart tissues, micro-tissues) to accurately assess cardiotoxicity and permeability of new cryoprotectant solutions
  • Develop innovative approaches to characterize cardiotoxicity of new compounds and their interactions with healthy heart function, including functional endpoints such as contractility, electrophysiology, and calcium handling
  • Apply plate-reader, flow cytometry-based and/or genomics techniques such as GWAS, RNA sequencing, and fluorescence in situ hybridization to inform and refine molecular discovery and in vitro models
  • Collaborate closely with cross-functional teams to translate experimental findings into new cryoprotectant solutions for human-sized organ preservation
  • Recruit and mentor team members and take on greater responsibility for experimental design and strategy as needed
Desired Qualifications
  • Experience evaluating pharmacokinetics and pharmacodynamics, with the ability to apply these frameworks to cryoprotectant formulation development
  • Experience with cardiac electrophysiology, contractility measurement, or calcium imaging techniques
  • Publication record in peer-reviewed journals in cardiac biology, cryobiology, toxicology, or related fields

UntilLabs develops reversible cryopreservation technology to extend the viability of human organs for transplantation. The goal is to keep organs alive at cryogenic temperatures long enough to improve organ matching and reduce waste from time limits, potentially weeks or months of preserved time. The approach uses cooling to very low temperatures (below -130°C) with cryoprotectants to prevent ice damage, followed by advanced warming methods to revive the organs without harm. While cryopreservation has worked for cells and simple tissues, UntilLabs works on scaling this to whole organs, tackling challenges like ice formation and nutrient/waste management in large tissues. In the long term, the company envisions whole-body reversible cryopreservation as a bridge to future medical cures.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

San Francisco, California

Founded

2024

Get referred to UntilLabs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Until Labs raised $58M on 2025-09-22 from Founders Fund, Lux, and Field Ventures.
  • Its 2026 careers page shows aggressive hiring across biology, engineering, legal, and operations.
  • The roadmap targets kidney, liver, heart validation and GLP studies for first-in-human trials.

What critics are saying

  • Organ cryopreservation remains scientifically unproven for human transplantation by 2026.
  • The 2025-09-22 Series A still funds research, not clinical product revenue.
  • Failure in large-animal organs before 2027 kills its transplant and hibernation thesis.

What makes UntilLabs unique

  • Until Labs combines organ perfusion, cryoprotectants, cooling, and rewarming hardware.
  • Its organ-scale focus directly targets transplant logistics, not distant whole-body speculation.
  • The 2026 alternating magnetic-field rewarming blog shows real engineering depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Flexible Work Hours

Paid Holidays

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Commuter Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

14%

1 year growth

14%

2 year growth

22%
Pioneer Publishers
Sep 22nd, 2025
Until Labs Secures $58M for Cryopreservation

Until Labs announced a $58 million Series A funding round led by Founders Fund, with Lux Capital and Field Ventures participating. The company focuses on developing technology for organ-scale reversible cryopreservation, allowing donor organs to be preserved indefinitely and rewarmed for transplant. The funding will help expand their multidisciplinary team to enhance their cryopreservation methods, aiming to improve organ matching and reduce organ waste.

Fenwick & West
Sep 22nd, 2025
Fenwick Represents Until Labs in $58M Series A Funding

Fenwick represents Until Labs in $58M Series A funding.